ProFunds Biotechnology UltraSector ProFund Inv (BIPIX)
48.63
+1.29
(+2.72%)
USD |
Sep 22 2025
Key Stats
Customize
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.56% | 67.73M | 0.22% | 196.0% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -22.02M | -12.60% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. Biotechnology Index for a single day. The Index seeks to measure the performance of certain companies in the biotechnology sector of the U.S. equity market. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Alternative Equity Leveraged |
| Peer Group | Equity Leverage Funds |
| Global Macro | Alternative Equity |
| US Macro | Large-Cap Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Equity Leverage Funds |
| Fund Owner Firm Name | ProFunds |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
77
-1.951B
Peer Group Low
220.95M
Peer Group High
1 Year
% Rank:
86
-22.02M
-6.876B
Peer Group Low
3.084B
Peer Group High
3 Months
% Rank:
80
-6.064B
Peer Group Low
704.04M
Peer Group High
3 Years
% Rank:
91
-14.44B
Peer Group Low
4.657B
Peer Group High
6 Months
% Rank:
81
-3.508B
Peer Group Low
1.296B
Peer Group High
5 Years
% Rank:
94
-5.236B
Peer Group Low
4.702B
Peer Group High
YTD
% Rank:
86
-4.995B
Peer Group Low
3.071B
Peer Group High
10 Years
% Rank:
96
-7.162B
Peer Group Low
7.479B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of September 23, 2025.
Asset Allocation
As of April 30, 2025.
| Type | % Net |
|---|---|
| Cash | 22.64% |
| Stock | 72.96% |
| Bond | 1.01% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 3.40% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
|
Societe Generale (London Branch) Repo
|
6.63% | -- | -- |
|
HSBC Securities (USA) Inc REPO
|
6.29% | -- | -- |
| Invesco Government & Agency Portfolio Inst | 3.25% | 1.00 | 0.00% |
|
Credit Agricole CIB New York REPO
|
2.38% | -- | -- |
|
Natwest Markets Plc REPO
|
2.29% | -- | -- |
| Alnylam Pharmaceuticals, Inc. | 2.07% | 456.21 | -0.59% |
| Natera, Inc. | 1.99% | 178.72 | -0.26% |
| Vertex Pharmaceuticals, Inc. | 1.96% | 380.67 | -0.64% |
|
UMB Financial Corp Repo
|
1.89% | -- | -- |
| Neurocrine Biosciences, Inc. | 1.89% | 146.90 | 0.19% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | 0.75% |
| Administration Fee | 501.5K% |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 15000.00 None |
| Minimum Subsequent Investment | 100.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. Biotechnology Index for a single day. The Index seeks to measure the performance of certain companies in the biotechnology sector of the U.S. equity market. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Alternative Equity Leveraged |
| Peer Group | Equity Leverage Funds |
| Global Macro | Alternative Equity |
| US Macro | Large-Cap Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Equity Leverage Funds |
| Fund Owner Firm Name | ProFunds |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (9-19-25) | 0.22% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Stock | |
| Weighted Average PE Ratio | 31.88 |
| Weighted Average Price to Sales Ratio | 17.31 |
| Weighted Average Price to Book Ratio | 8.870 |
| Weighted Median ROE | -46.36% |
| Weighted Median ROA | -17.43% |
| ROI (TTM) | -20.42% |
| Return on Investment (TTM) | -20.42% |
| Earning Yield | 0.0497 |
| LT Debt / Shareholders Equity | 2.691 |
As of April 30, 2025
Growth Metrics
| EPS Growth (1Y) | 18.27% |
| EPS Growth (3Y) | 6.62% |
| EPS Growth (5Y) | 2.94% |
| Sales Growth (1Y) | 26.33% |
| Sales Growth (3Y) | 20.62% |
| Sales Growth (5Y) | 29.60% |
| Sales per Share Growth (1Y) | 1.06K% |
| Sales per Share Growth (3Y) | 21.76% |
| Operating Cash Flow - Growth Ratge (3Y) | 9.53% |
As of April 30, 2025
Fund Details
| Key Dates | |
| Inception Date | 6/19/2000 |
| Last Annual Report Date | 7/31/2024 |
| Last Prospectus Date | 11/27/2024 |
| Share Classes | |
| BIPSX | Service |
| Attributes | |
| Index Fund | -- |
| Inverse Fund | -- |
| Leveraged Fund |
|
| Fund of Funds | No |
| Currency Hedged Fund | -- |
| Synthetic Replication Fund | No |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:BIPIX", "name") |
| Broad Asset Class: =YCI("M:BIPIX", "broad_asset_class") |
| Broad Category: =YCI("M:BIPIX", "broad_category_group") |
| Prospectus Objective: =YCI("M:BIPIX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |